Cancer has one of the highest mortality rates of all diseases worldwide. In Japan too it is the number one cause of death, and naturally, there is an urgent need for new drugs. In 1983 Otsuka established the Fujii Memorial Research Institute (originally the Biwako Research Institute), and has been engaged in anti-cancer drug research since, especially in the field of blood cancers, aspiring to help cancer patients worldwide. Otsuka is providing new treatment options in collaboration with both domestic and foreign collaborators.
In 2008, Otsuka Pharmaceutical acquired the entire business built around the drug for the conditioning regimen prior to hematopoietic progenitor cell transplantation and rolled out the product globally. As a pre-treatment prior to hematopoietic progenitor cell transplantation carried out as a part of treatment for all forms of blood cancer, this drug is contributing to patients as a necessary drug that ranks alongside radiation therapy.